Literature DB >> 2145914

Epirubicin for pretreated advanced ovarian cancer.

R Coleman, K Towlson, E Wiltshaw, M Slevin, P Blake, R Stein, R Coombes, P Harper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2145914     DOI： 10.1016/0277-5379(90)90173-q

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  4 in total

Review 1.  Current drug treatment guidelines for epithelial ovarian cancer.

Authors:  P C Lorigan; T Crosby; R E Coleman
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 2.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

3.  Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.

Authors:  A du Bois; H G Meerpohl; H Madjar; D Spinner; P Dall; J Pfisterer; T Bauknecht
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease.

Authors:  M T Seymour; J L Mansi; C J Gallagher; M E Gore; P G Harper; T R Evans; P M Edmonds; M L Slevin
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.